Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224146 · ClinicalTrials.gov registry record · Phase 4
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
A Phase 4 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,878
- Enrollment target
NCT00224146 is a Phase 4 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 2,878 participants.
The verdict
NCT00224146, a Phase 4 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,878 participants
- Enrollment target
Study Summary
This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)
Interventions
- DRUG oxybutynin transdermal delivery system (Oxytrol(r))
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,878 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224146
The ClinicalTrials.gov registry entry for NCT00224146 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2,878 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oxybutynin transdermal delivery system (Oxytrol(r)) is the first listed.
NCT00224146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00224146 about?
NCT00224146 is a clinical study titled "Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder". This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)
What is the current status of trial NCT00224146?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,878 participants. The study started on 2004-05. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00224146?
The interventions under investigation include: oxybutynin transdermal delivery system (Oxytrol(r)) (DRUG).
Who is sponsoring clinical trial NCT00224146?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.